Reduction in Clostridium difficile environmental contamination by hospitalized patients treated with fidaxomicin

J S Biswas; A Patel; J A Otter; P Wade; W Newsholme; E van Kleef; S D Goldenberg

doi:10.1016/j.jhin.2015.01.015

Reduction in Clostridium difficile environmental contamination by hospitalized patients treated with fidaxomicin

J Hosp Infect. 2015 Jul;90(3):267-70. doi: 10.1016/j.jhin.2015.01.015. Epub 2015 Feb 9.

Authors

J S Biswas¹, A Patel¹, J A Otter¹, P Wade¹, W Newsholme¹, E van Kleef², S D Goldenberg³

Affiliations

¹ Centre for Clinical Infection and Diagnostics Research, King's College, London and Guy's & St Thomas' NHS Foundation Trust, London, UK.
² London School of Hygiene and Tropical Medicine, London, UK; Public Health England, Colindale, London, UK.
³ Centre for Clinical Infection and Diagnostics Research, King's College, London and Guy's & St Thomas' NHS Foundation Trust, London, UK. Electronic address: simon.goldenberg@gstt.nhs.uk.

PMID: 25728208
DOI: 10.1016/j.jhin.2015.01.015

Abstract

Fidaxomicin is sporicidal and may be associated with a reduced time to resolution of diarrhoea when used to treat patients with Clostridium difficile infection (CDI). This study investigated whether fidaxomicin for treatment of all patients with CDI reduced C. difficile environmental contamination. Surfaces in the rooms of 66 hospitalized patients treated with metronidazole and/or vancomycin and 68 hospitalized patients treated with fidaxomicin were sampled. Patients treated with fidaxomicin were less likely to contaminate their environment (25/68, 36.8%) than patients treated with metronidazole and/or vancomycin (38/66 57.6%) (P = 0.02). Treatment with fidaxomicin was associated with reduced environmental contamination with C. difficile.

Keywords: Clostridium difficile; Contamination; Environment; Fidaxomicin.

Publication types

Randomized Controlled Trial
Research Support, Non-U.S. Gov't

MeSH terms

Adult
Aminoglycosides / therapeutic use*
Anti-Bacterial Agents / therapeutic use*
Clostridioides difficile / drug effects
Clostridioides difficile / isolation & purification*
Clostridium Infections / drug therapy*
Clostridium Infections / microbiology*
Cross Infection / microbiology
Cross Infection / prevention & control
Diarrhea / drug therapy*
Diarrhea / microbiology*
Environmental Microbiology
Female
Fidaxomicin
Hospitalization
Humans
Male
Metronidazole / therapeutic use
Vancomycin / therapeutic use

Substances

Aminoglycosides
Anti-Bacterial Agents
Metronidazole
Vancomycin
Fidaxomicin